Liberty One Investment Management LLC Buys 9,079 Shares of Lantheus Holdings, Inc. $LNTH

Liberty One Investment Management LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 85.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,713 shares of the medical equipment provider’s stock after acquiring an additional 9,079 shares during the quarter. Liberty One Investment Management LLC’s holdings in Lantheus were worth $1,013,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Focus Financial Network Inc. increased its holdings in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after acquiring an additional 136 shares in the last quarter. Park Avenue Securities LLC grew its position in Lantheus by 6.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,841 shares of the medical equipment provider’s stock valued at $233,000 after purchasing an additional 179 shares during the last quarter. Moody National Bank Trust Division increased its stake in Lantheus by 1.2% during the 2nd quarter. Moody National Bank Trust Division now owns 15,095 shares of the medical equipment provider’s stock valued at $1,236,000 after purchasing an additional 185 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Lantheus by 20.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock valued at $103,000 after purchasing an additional 212 shares in the last quarter. Finally, First National Advisers LLC raised its holdings in Lantheus by 0.8% in the second quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock worth $2,292,000 after buying an additional 213 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. Truist Financial increased their price target on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. TD Cowen reduced their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Finally, Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Stock Performance

LNTH stock opened at $67.48 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a market cap of $4.47 billion, a P/E ratio of 28.35 and a beta of -0.11. The stock’s fifty day moving average price is $61.36 and its 200-day moving average price is $61.20.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.27. The company had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.Lantheus’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.70 earnings per share. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.